Investor Kit

Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
05/10/18
Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
06/15/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
06/15/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
06/15/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
06/15/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
06/15/184Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
06/19/18Pacira Pharmaceuticals and Nuance Biotech Announce License Agreement for EXPAREL® in China
PARSIPPANY, N.J. and SHANGHAI, China, June 19, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) and Nuance Biotech Co. Ltd (Nuance) today announced that they have entered into an agreement with Nuance, a China based specialty pharmaceutical company, to advance the development and commercialization of EXPAREL® (bupivacaine liposome injectable suspension) in China. EXPAREL is a non-opioid option for achieving long-lasting pain control after surgery via infiltration into the su... 
Printer Friendly Version
06/15/18Aetna DocFind Directory Now Highlights Providers Offering Opioid Alternatives, Including EXPAREL®
DocFind update helps Aetna members connect with surgeons trained in managing postsurgical pain using non-opioid medications PARSIPPANY, N.J., June 15, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. today announced further collaboration with Aetna, one of the nation’s leading diversified health care benefits companies. Aetna has updated its online provider directory, DocFind, to help members easily identify surgeons who are committed to offering opioid alternatives, including EXPAREL® (... 
Printer Friendly Version
06/13/18MEDNAX National Medical Group and Pacira Pharmaceuticals Launch National Enhanced Recovery after Cesarean Surgery (ERACS™) Collaborative to Minimize Opioid Use
FORT LAUDERDALE, Fla., June 13, 2018 – MEDNAX, Inc. (NYSE:MD), the national health solutions partner specializing in anesthesiology, neonatology, maternal-fetal medicine, other pediatric services, radiology and management services, is pleased to announce that it has partnered with Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to address the ongoing use of opioids during and after cesarean surgery by launching a national collaborative aimed at addressing the Quadruple Aim throu... 
Printer Friendly Version
05/31/18Pacira Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference
PARSIPPANY, N.J., May 31, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported that Dave Stack, chairman and chief executive officer, will present at the Jefferies 2018 Healthcare Conference at 9:30 AM ET on Tuesday, June 5, 2018. Live audio of the presentation can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira Pacira Pharm... 
Printer Friendly Version
05/03/18Pacira Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results
-- EXPAREL® net product sales of $74.0 million up 9% over prior year first quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 03, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated financial results for the first quarter ended March 31, 2018. “2018 is off to a terrific start with EXPAREL daily sales volumes accelerating from 6 percent in January to 15 percent in March, as well as a recently expanded label that now inclu... 
Printer Friendly Version
05/01/18Pacira Pharmaceuticals to Present at Two Healthcare Conferences in May
PARSIPPANY, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the following two healthcare conferences: Deutsche Bank 43rd Annual Health Care Conference in Boston, on Wednesday, May 9 at 2:10 PM ET Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, on Tuesday, May 15, at 1:40 PM PT (4:40PM ET) A live audio webcast of the Pacira presentations can be ac... 
Printer Friendly Version
04/26/18Pacira Pharmaceuticals Announces Timing for First Quarter 2018 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 3, 2018. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team. The call can be accessed by dialing 1-... 
Printer Friendly Version
04/06/18Pacira Announces FDA Approval of Supplemental New Drug Application for EXPAREL® as a Nerve Block to Produce Regional Analgesia
EXPAREL is now an opioid-free option for use as an interscalene brachial plexus block for upper extremity surgeries Conference call on Monday, April 9, 2018 at 8:30 a.m. EST PARSIPPANY, N.J., April 06, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) to broaden the use of EXPAREL® (bupivacaine liposome injectable suspension) to include administratio... 
Printer Friendly Version
03/06/18Pacira Pharmaceuticals to Present at the 2018 Barclays Global Healthcare Conference
PARSIPPANY, N.J., March 06, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to participate in an analyst-led fireside chat at the 2018 Barclays Global Healthcare Conference at 11:15 AM ET on Tuesday, March 13, 2018 in Miami. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on... 
Printer Friendly Version
02/28/18Pacira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
-- EXPAREL® net product sales expected to be in the range of $300 to $310 million in 2018 -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported financial results for the fourth quarter and full year of 2017 and its outlook for 2018. “2017 was a year of solid progress and set the stage for an important year ahead,” said Dave Stack, chairman and chief executive officer of Pacira. “EXPAREL ... 
Printer Friendly Version
>> Access Older Press Releases